Lexicon Pharmaceuticals Still On The Launch Pad, With An Uncertain Trajectory
magicmine/iStock via Getty Images
Biotech is hard. Most biotechs never manage to develop one drug that can get through the FDA approval process, let alone two. With Lexicon Pharmaceuticals (LXRX), though, investors are getting a difficult lesson that while…
